Trial intelligence / Profile preview

Exosome injection during laparoscopic cesarean scar niche repair

IRCT20091012002576N36Phase 3Completed

Sponsor
Tehran University of Medical Sciences
Start
Mar 2024
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Countries
1
01

Overview

Phase 3, randomised, triple-blind trial of endothelial progenitor cell-derived exosomes in Caesarean scar defect (CSD) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Evaluation of niche by transvaginal sonogram. Started Mar 2024; status: completed.

02

Drugs

endothelial progenitor cell-derived exosomes
03

Conditions

Caesarean scar defect (CSD)

Beyond the preview

Go deeper on IRCT20091012002576N36.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20091012002576N36.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call